Peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3]octreotate in combination with RAD001 treatment: further investigations on tumor metastasis and response in the rat pancreatic CA20948 tumor model

EJNMMI Research

Table 2 Overview of tumor responses

Experiment	Group	CR (%)	PR (%)	Rats with metastases (%)	n
1	Control^a	0	0	0	7
	RAD 5 mg/kg^a	0	0	0	6
	¹⁷⁷Lu-TATE 125 MBq	57	29	0	7
	¹⁷⁷Lu-TATE 278 MBq	71	29	0	7
	RAD 5 mg/kg + ¹⁷⁷Lu-TATE 125 MBq	29	57	71	7
	RAD 5 mg/kg + ¹⁷⁷Lu-TATE 278 MBq	14	57	86	7
2	Control^b	0	0	0	8
	RAD 5.0 mg/kg^b	0	13	75	8
	RAD 2.5 mg/kg^b	13	0	63	8
	¹⁷⁷Lu-TATE 125 MBq^b	43	57	0	7
	¹⁷⁷Lu-TATE 125 MBq + RAD 5.0 mg/kg^b	0	63	88	8
	¹⁷⁷Lu-TATE 125 MBq + RAD 2.5 mg/kg^b	14	43	86	7
3	Control^b	50	0	0	8
	RAD 4.5 weeks^b	12.5	12.5	37.5	8
	RAD 12 weeks^b	12.5	25	50	8
	¹⁷⁷Lu-TATE 125 MBq + RAD 4.5 weeks^b	87.5	12.5	12.5	8
	¹⁷⁷Lu-TATE 125 MBq + RAD 12 weeks^b	75	25	25	8

^aRats did not survive until 42 to 146 days post start of treatment (p.t.), the time frame in which metastases became apparent in the other groups, because rats had to be euthanized when primary tumor size was >4 to 6 cm³. ^bPrimary tumors were surgically removed when tumor size was >4 to 6 cm³. CR, complete response (100% reduction of tumor size); PR, partial response (>50% reduction of tumor volume but no CR); n, number of animals/group; ¹⁷⁷Lu-TATE, ¹⁷⁷Lu-DOTA⁰, Tyr³-octreotate; RAD, RAD001.